StockNews.AI
TARS
StockNews.AI
117 days

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

1. Tarsus Pharmaceuticals will host a financial results webcast on May 1, 2025. 2. XDEMVY® is FDA approved for Demodex blepharitis treatment. 3. Tarsus is advancing therapies for ocular diseases and Lyme disease prevention. 4. Investors can access the webcast; a recording will be archived for 90 days.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results could exceed expectations, likely boosting investor confidence. Historical examples show that positive earnings calls typically drive stock prices up.

How important is it?

The webcast indicates ongoing corporate transparency, important for investor trust and potential stock price appreciation.

Why Short Term?

The webcast's results are immediate catalysts for price movement. Similar past earnings releases often led to quick upward price responses.

Related Companies

XDEMVYTP-04TP-05
April 24, 2025 17:00 ET  | Source: Tarsus Pharmaceuticals, Inc IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801AKemp@tarsusrx.com Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com

Related News